Nerandomilast primary endpoint phase-3 FIBRONEER-IPF met Nerandomilast primary endpoint phase-3 FIBRONEER-IPF met Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study
2024 half year results innovation progress 2024 half year results innovation progress First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones